期刊
PRENATAL DIAGNOSIS
卷 42, 期 7, 页码 873-880出版社
WILEY
DOI: 10.1002/pd.6168
关键词
-
资金
- Clinical Research Plan of SHDC [SHDC2020CR6028-005]
- National Natural Science Foundation of China [81871174, 82071656]
- National Key R&D Program of China [2018YFC1002900]
- Science and Technology Commission of Shanghai Municipality [21Y11907500]
This study investigated the use of chromosomal microarray (CMA) and exome sequencing (ES) in fetuses with congenital heart disease (CHD). The results showed that CMA should be offered as a first-line genetic test in pregnancies complicated by both isolated and non-isolated cardiac abnormalities. When CMA is non-diagnostic, ES can be considered to add diagnostic value.
Objective To investigate the use of chromosomal microarray (CMA) and Exome sequencing (ES) in fetuses with congenital heart disease (CHD). Methods The Fetal Medicine Unit of Shanghai First Maternity and Infant Hospital records were reviewed to ascertain all cases diagnosed with CHD by level 2 ultrasound examination between 2016 and 2019. Cases were categorized as isolated or associated with other abnormalities or fetal growth restriction. CMA was offered to all cases as a first-line genetic test followed by ES when CMA was non-diagnostic. Results Of the 586 ascertained, 84 (14.3%) had causative CMA abnormality, of which 8.8% (35/400) were in fetuses with isolated CHD and 26.3% (49/186) in those with other abnormalities. ES was performed in 47 cases with a negative CMA. Causative variants were identified in two (10.5%, 2/19) isolated cases and four(14.3%, 4/28) with other abnormalities. Conclusion Invasive procedures with CMA should be offered in pregnancies complicated by both non-isolated and isolated cardiac abnormalities. When CMA is not diagnostic, ES can add diagnostic value in both groups and should be considered even for fetuses with an isolated CHD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据